The civic record
Read. Follow. Verify.Iowa requires health and administrative departments to review anti-obesity medications and report by January 2026
Last action · June 16, 2025: Referred to Health and Human Services. S.J. 1058 .
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
Senate File 552 requires the Department of Health and Human Services and the Department of Administrative Services to review anti-obesity medications, including , for effectiveness, cost impacts, and eligibility requirements, and submit a report to the General Assembly by January 5, 2026.
The measure establishes a formal evaluation process that could shape future prescription drug coverage rules and state expenditures for Medicaid recipients and public-sector workers.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Medicaid recipients
Their medical assistance program is subject to a review that could establish eligibility rules and coverage options for anti-obesity medications.
state employees
State employee health insurance plans under chapter 509A are included in the mandatory medication review and potential coverage recommendations.
Key Facts
- The Department of Health and Human Services and the Department of Administrative Services must review anti-obesity medications, including GLP-1 agonists.
- The review applies to the medical assistance program under chapter 249A and state employee health insurance plans under chapter 509A.
- The departments must evaluate weight-loss effectiveness, impacts on comorbidities, potential cost savings from deferred medical procedures, and recommended eligibility requirements.
- The departments must submit a findings report to the General Assembly by January 5, 2026.
Show all 5 facts
- The report must include proposed eligibility requirements and short-term and long-term costs associated with coverage.
Frequently Asked Questions
What agencies are responsible for conducting the review?
When is the report due to the General Assembly?
Which health programs or plans are covered by this review?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
8 actions- Jun 16, 2025SenateCommitteeReferred to Health and Human Services. S.J. 1058 .
- Mar 6, 2025SenateCommittee report, approving bill. S.J. 436 .
- Mar 6, 2025SenateIntroducedIntroduced, placed on calendar. S.J. 431 .
- Mar 5, 2025Iowa LegislatureCommittee report approving bill, renumbered as SF 552 .
- Feb 20, 2025Iowa LegislatureSubcommittee recommends amendment and passage.
- Feb 18, 2025Iowa LegislatureSubcommittee Meeting: 02/19/2025 3:30PM Room G15.
Show 2 earlier actions
- Feb 18, 2025Iowa LegislatureSubcommittee: Klimesh, Salmon, and Wahls.
- Feb 18, 2025Iowa LegislatureIntroducedIntroduced, referred to Health and Human Services.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Connected Entities
Sources
www.legis.iowa.gov
Analysis Score
0–100- Significance45How much this matters to a regular citizen
- Controversy25Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz35Current news / social attention level
Publisher tools